{"id":"tipranavir-ritonavir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tipranavir works by inhibiting the protease enzyme, which is essential for the replication of the HIV-1 virus. This action prevents the virus from producing new viral particles, thereby reducing the viral load in the body.","oneSentence":"Tipranavir/Ritonavir is a protease inhibitor used in combination with other medications to treat HIV-1 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:53.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Treatment of HIV-1 infection in combination with other antiretroviral agents"}]},"trialDetails":[{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT02249442","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-10-01","conditions":"Hepatic Insufficiency","enrollment":24},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT00275444","phase":"PHASE2","title":"3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-03-29","conditions":"HIV Infections","enrollment":216},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT01276236","phase":"PHASE2","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03-09","conditions":"Kaposi's Sarcoma","enrollment":13},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00486330","phase":"NA","title":"Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-05","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00607958","phase":"PHASE4","title":"Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-12","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT01068925","phase":"PHASE1","title":"Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-02-15","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":18},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT00933205","phase":"","title":"An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.","status":"APPROVED_FOR_MARKETING","sponsor":"Boehringer Ingelheim","startDate":"2004-05","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00097799","phase":"","title":"Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection","status":"APPROVED_FOR_MARKETING","sponsor":"Boehringer Ingelheim","startDate":"2004-12","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00062660","phase":"","title":"Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection","status":"APPROVED_FOR_MARKETING","sponsor":"Boehringer Ingelheim","startDate":"2003-05","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00344123","phase":"PHASE1","title":"Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-02","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT02257021","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-02","conditions":"Healthy","enrollment":34},{"nctId":"NCT02253888","phase":"PHASE1","title":"Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT02253836","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-01","conditions":"Healthy","enrollment":21},{"nctId":"NCT02253849","phase":"PHASE1","title":"Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":"Healthy","enrollment":28},{"nctId":"NCT02253862","phase":"PHASE1","title":"Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-12","conditions":"Healthy","enrollment":17},{"nctId":"NCT02253875","phase":"PHASE1","title":"Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":"Healthy","enrollment":15},{"nctId":"NCT02253823","phase":"PHASE1","title":"Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-12","conditions":"Healthy","enrollment":68},{"nctId":"NCT02253797","phase":"PHASE1","title":"Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Healthy","enrollment":""},{"nctId":"NCT02251795","phase":"PHASE1","title":"Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-08","conditions":"Healthy","enrollment":52},{"nctId":"NCT02251119","phase":"PHASE1","title":"The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT02251769","phase":"PHASE1","title":"Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02251145","phase":"PHASE1","title":"Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Healthy","enrollment":49},{"nctId":"NCT02251171","phase":"PHASE1","title":"Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02251223","phase":"PHASE1, PHASE2","title":"Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-02","conditions":"HIV Infections","enrollment":208},{"nctId":"NCT02251873","phase":"PHASE1","title":"Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Healthy","enrollment":50},{"nctId":"NCT02251158","phase":"PHASE1","title":"Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT02251132","phase":"PHASE1","title":"Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Healthy","enrollment":113},{"nctId":"NCT02248883","phase":"PHASE1","title":"Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-12","conditions":"Healthy","enrollment":81},{"nctId":"NCT02249130","phase":"PHASE2","title":"Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-03","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT02249416","phase":"PHASE1","title":"Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-11","conditions":"Healthy","enrollment":60},{"nctId":"NCT02245451","phase":"PHASE1","title":"Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT02245269","phase":"PHASE1","title":"Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT02245438","phase":"PHASE1","title":"Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Healthy","enrollment":52},{"nctId":"NCT02244190","phase":"PHASE1","title":"Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT02243553","phase":"PHASE1","title":"Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01","conditions":"Healthy","enrollment":34},{"nctId":"NCT02239835","phase":"PHASE2","title":"Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-12","conditions":"HIV Infections","enrollment":79},{"nctId":"NCT02238314","phase":"PHASE2","title":"Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-01","conditions":"HIV Infections","enrollment":41},{"nctId":"NCT02229760","phase":"PHASE1, PHASE2","title":"Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2006-08","conditions":"HIV Infections","enrollment":3},{"nctId":"NCT02227017","phase":"PHASE1","title":"Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-02","conditions":"Healthy","enrollment":35},{"nctId":"NCT02226991","phase":"PHASE1","title":"Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02226978","phase":"PHASE1","title":"Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"Healthy","enrollment":29},{"nctId":"NCT02195466","phase":"PHASE1","title":"Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00144170","phase":"PHASE3","title":"Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"HIV Infections","enrollment":882},{"nctId":"NCT00054717","phase":"PHASE3","title":"Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"HIV Infections","enrollment":630},{"nctId":"NCT00440271","phase":"PHASE3","title":"SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT00530920","phase":"PHASE2","title":"Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00447902","phase":"PHASE3","title":"Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00517192","phase":"PHASE3","title":"Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00076999","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00531206","phase":"","title":"Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-08","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT00976950","phase":"","title":"A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-09","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00146328","phase":"PHASE2, PHASE3","title":"Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-04","conditions":"HIV Infections","enrollment":997},{"nctId":"NCT00144287","phase":"PHASE3","title":"Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-05","conditions":"HIV Infections","enrollment":255},{"nctId":"NCT00144105","phase":"PHASE2","title":"A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2004-02","conditions":"HIV Infections","enrollment":562},{"nctId":"NCT00966329","phase":"PHASE4","title":"Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV, HIV Infections","enrollment":30},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00352066","phase":"PHASE1","title":"Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together","status":"COMPLETED","sponsor":"Avexa","startDate":"2006-07","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT00034866","phase":"PHASE2","title":"Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-04","conditions":"HIV Infections","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":73,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aptivus"],"phase":"phase_3","status":"active","brandName":"Tipranavir/Ritonavir","genericName":"Tipranavir/Ritonavir","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tipranavir/Ritonavir is a protease inhibitor used in combination with other medications to treat HIV-1 infection. Used for Treatment of HIV-1 infection in adults and children, Treatment of HIV-1 infection in combination with other antiretroviral agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}